ConductScience.org, home

Paper42731007

[Anthracycline use in breast cancer based on our current knowledge].

Rubovszky G and 2 others. Magy Onkol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. [Anthracycline use in breast cancer based on our current knowledge]. Papers, record 42731007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42731007

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[Anthracycline use in breast cancer based on our current knowledge].
PubMed
Journal
Magy Onkol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review, English Abstract
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-17
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rubovszky GGábor
2Nikolényi AAlíz
3Boér KKatalin

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
AnthracyclinesMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Antineoplastic AgentsMajor topic
Antibiotics, AntineoplasticMajor topic
Humans
Female
Treatment Outcome
Erb-b2 Receptor Tyrosine Kinases
Chemotherapy, Adjuvant

Source PubMed

Download CSV of topics

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11462166The anthracyclines: will we ever find a better doxorubicin?Semin Oncol1992https://conductscience.org/library/papers/1462166PubMed
239396348Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.Lancet2024https://conductscience.org/library/papers/39396348PubMed
330739743Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.Lancet2019https://conductscience.org/library/papers/30739743PubMed
432258060Cardiotoxicity of Anthracyclines.Front Cardiovasc Med2020https://conductscience.org/library/papers/32258060PubMed
517135639Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.J Clin Oncol2006https://conductscience.org/library/papers/17135639PubMed
636858723Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Lancet Oncol2023https://conductscience.org/library/papers/36858723PubMed
722392196Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis.Med Oncol2012https://conductscience.org/library/papers/22392196PubMed
840618711Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis.Breast2025https://conductscience.org/library/papers/40618711PubMed
921681601Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.Pathol Oncol Res2012https://conductscience.org/library/papers/21681601PubMed
1022152853Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.Lancet2012https://conductscience.org/library/papers/22152853PubMed
1138173817Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention.Front Cardiovasc Med2023https://conductscience.org/library/papers/38173817PubMed
1229236294Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.Cancer2018https://conductscience.org/library/papers/29236294PubMed
1328398846Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).J Clin Oncol2017https://conductscience.org/library/papers/28398846PubMed
1438335467Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).J Clin Oncol2024https://conductscience.org/library/papers/38335467PubMed
1521917518HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.Lancet Oncol2011https://conductscience.org/library/papers/21917518PubMed
1639556787Pregnancy-Associated Breast Cancer: Key Concepts for Optimizing Diagnosis and Treatment.JCO Oncol Pract2025https://conductscience.org/library/papers/39556787PubMed
1741436191
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
BMJ2025https://conductscience.org/library/papers/41436191PubMed
1839479333Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review.JACC CardioOncol2024https://conductscience.org/library/papers/39479333PubMed
1931289672Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment.Mol Clin Oncol2019https://conductscience.org/library/papers/31289672PubMed
2039143082Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.NPJ Breast Cancer2024https://conductscience.org/library/papers/39143082PubMed

See all 26 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42731007

GET https://conductscience.org/api/papers/v1/42731007/references?page=2